CorMedix (NASDAQ:CRMD) Trading Down 5.9% – Time to Sell?

Posted by Brian Himes on Jun 25th, 2026

CorMedix Inc (NASDAQ:CRMD – Get Free Report) shares traded down 5.9% on Thursday . The stock traded as low as $7.96 and last traded at $7.8940. Approximately 600,994 shares traded hands during mid-day trading, a decline of 68% from the average daily volume of 1,858,694 shares. The stock had previously closed at $8.39.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on the stock. Citizens Jmp reissued a “market outperform” rating and issued a $19.00 price target on shares of CorMedix in a report on Tuesday, April 28th. Royal Bank Of Canada reaffirmed an “outperform” rating and set a $14.00 price objective (up from $13.00) on shares of CorMedix in a research note on Tuesday, April 28th. Needham & Company LLC boosted their target price on CorMedix from $14.00 to $15.00 and gave the company a “buy” rating in a research note on Monday, April 27th. Leerink Partners increased their price target on CorMedix from $13.00 to $14.00 and gave the stock an “outperform” rating in a report on Tuesday, April 28th. Finally, Weiss Ratings raised CorMedix from a “hold (c-)” rating to a “hold (c)” rating in a research report on Thursday, May 14th. Six investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $15.00.

View Our Latest Research Report on CRMD

CorMedix Trading Down 6.2%

The company has a quick ratio of 2.74, a current ratio of 2.97 and a debt-to-equity ratio of 0.33. The business’s fifty day moving average is $8.04 and its 200 day moving average is $8.22. The firm has a market capitalization of $617.32 million, a price-to-earnings ratio of 3.70 and a beta of 1.46.

CorMedix (NASDAQ:CRMD – Get Free Report) last announced its earnings results on Thursday, May 14th. The company reported $0.43 earnings per share for the quarter, topping analysts’ consensus estimates of $0.35 by $0.08. The firm had revenue of $127.43 million during the quarter, compared to analyst estimates of $104.96 million. CorMedix had a net margin of 45.25% and a return on equity of 45.57%. The company’s revenue for the quarter was up 226.1% compared to the same quarter last year. During the same period in the prior year, the business earned $0.30 EPS. Equities analysts predict that CorMedix Inc will post 0.53 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the company. Russell Investments Group Ltd. raised its position in CorMedix by 22.2% in the 2nd quarter. Russell Investments Group Ltd. now owns 6,553 shares of the company’s stock valued at $81,000 after buying an additional 1,190 shares during the last quarter. Gryphon Financial Partners LLC grew its stake in shares of CorMedix by 6.3% during the 1st quarter. Gryphon Financial Partners LLC now owns 27,401 shares of the company’s stock worth $186,000 after acquiring an additional 1,618 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in shares of CorMedix by 4.7% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 35,987 shares of the company’s stock valued at $222,000 after purchasing an additional 1,631 shares during the last quarter. Wealth Enhancement Advisory Services LLC raised its holdings in shares of CorMedix by 6.6% in the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 27,540 shares of the company’s stock valued at $310,000 after purchasing an additional 1,707 shares during the last quarter. Finally, Financial Management Professionals Inc. bought a new stake in shares of CorMedix in the fourth quarter worth $25,000. 34.18% of the stock is owned by institutional investors and hedge funds.

CorMedix Company Profile

(Get Free Report)

CorMedix Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to reduce inflammation and prevent infection in critically and chronically ill patient populations. The company’s lead product candidate, Neutrolin, is a catheter lock solution that combines taurolidine, heparin and citrate to prevent catheter-related bloodstream infections (CRBSIs) in patients undergoing hemodialysis. Neutrolin has received market authorization in the European Union under the CE Mark and is positioned to address a significant unmet medical need for infection prevention in dialysis centers.

In addition to its lead asset, CorMedix is advancing a biochemical portfolio aimed at mitigating complications associated with peritoneal dialysis and other high-risk procedures.